consortium in 2019. Since that time, the Lab Owl product has been integrated into ARMI’s Tissue Foundry manufacturing process, and the Lab Owl team has made important contributions to several working groups tasked with solving some of the challenges facing tissue engineering and regenerative medicine manufacturing. These working groups include establishing ARMI’s Workforce Characteristics Charter; the Tissue Maturation and Bioreactor Charter; and the Cell Culture and Harvest Charter.
In 2020 we introduced a new series titled “5 Questions With…” in an effort to spotlight individuals from across the BioHealth Capital Region and beyond. Providing this platform has allowed us to help share the stories of industry peers and show that there isn’t a single “right” way to becoming an industry success.
Kurt Elam joined ACC/Lab Owl in 2017 with 20+ years of specialty biopharmaceutical experience, focused primarily on oncology, infectious disease, and critical care/ICU medicine. He has overseen and managed the successful launch of over 16 new FDA approved products/compounds or new indications, and worked to gain formulary approval in managed care organizations, thereby improving access for patients.
Experts Weigh in on the Role of Lab Automation and Sensor Technology in Advancing the Cell Therapy and Regenerative Medicine Fields
While there is tremendous excitement and ample investment around cell and gene therapy and regenerative medicine, several challenges, including scale-up, high manufacturing costs, and regulatory hurdles, continue to be impediments to the industry achieving its potential.
Stem Cell Experts from Maryland presenting at Phacilitate World Stem Cell Summit
Top 10 Biotech News Stories from 2019 from the BioHealth Capital Region on biobuzz.io
BIO 2019 Maryland Pavilion